Novavax Inc (NVAX) Stock Price

NVAXStock

$11.26+32.78%52W

Market Cap$1.86B

P/E4.22x

PEG Ratio1.32

Div yield—

Beta2.81

NVAX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)24.30%

Price vs S&P 500 (4W)9.49%

PEG Ratio1.32

VGM Score54.56

P/E Ratio (Annual)4.22x

Book Value / Share (Quarterly)$0.23

P/TBV (Annual)11.42x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-17.24%

Cash Flow / Share (Quarterly)$-0.26

Price vs S&P 500 (YTD)55.63%

Gross Margin (TTM)79.16%

Net Profit Margin (TTM)-59.87%

EPS (TTM)$-1.54

10-Day Avg Trading Volume12.44M

EPS Excl Extra (TTM)$-1.54

Revenue Growth (5Y)18.76%

EPS (Annual)$2.54

ROI (Annual)-38.19%

Gross Margin (Annual)93.50%

Net Profit Margin (5Y Avg)-45.81%

Cash / Share (Quarterly)$4.36

P/E Basic Excl Extra (TTM)3.80x

Revenue Growth QoQ (YoY)-76.30%

P/E Normalized (Annual)4.22x

ROA (Last FY)-12.02%

Revenue Growth TTM (YoY)-61.64%

EBITD / Share (TTM)$-1.45

ROE (5Y Avg)-43.51%

Operating Margin (TTM)-63.52%

Cash Flow / Share (Annual)$-0.63

P/B Ratio49.36x

P/B Ratio (Quarterly)27.12x

Net Income / Employee (Annual)$587,900

EV / Revenue (TTM)4.74x

Net Interest Coverage (TTM)20.61x

ROA (TTM)-22.75%

EV / EBITDA (TTM)4.35x

EPS Incl Extra (Annual)$2.54

Current Ratio (Annual)0.98x

Quick Ratio (Quarterly)2.23x

3-Month Avg Trading Volume5.35M

52-Week Price Return32.78%

P/E Incl Extra (TTM)3.80x

Revenue / Employee (TTM)$552,500

Tangible BV / Share (Quarterly)$0.78

P/S Ratio (Annual)1.65x

Asset Turnover (Annual)0.44x

52-Week High$13.38

Operating Margin (5Y Avg)-47.20%

EPS Excl Extra (Annual)$2.54

CapEx CAGR (5Y)-36.67%

Tangible BV CAGR (5Y)66.48%

26-Week Price Return34.21%

Quick Ratio (Annual)0.92x

13-Week Price Return37.15%

Total Debt / Equity (Annual)0.75x

Current Ratio (Quarterly)2.33x

Enterprise Value$1.96B

Revenue / Share Growth (5Y)-4.70%

Asset Turnover (TTM)0.38x

Book Value / Share Growth (5Y)-0.67%

Revenue / Employee (Annual)$1,500,000

Inventory Turnover (Annual)8.00x

Pretax Margin (Annual)39.36%

Cash / Share (Annual)$5.77

3-Month Return Std Dev75.03%

Gross Margin (5Y Avg)66.92%

Net Income / Employee (TTM)$-330,700

ROE (Last FY)-66.69%

Net Interest Coverage (Annual)-14.53x

EPS Basic Excl Extra (Annual)$2.54

P/FCF (TTM)17.56x

Receivables Turnover (TTM)3.38x

Total Debt / Equity (Quarterly)6.07x

EPS Incl Extra (TTM)$-1.54

Receivables Turnover (Annual)5.18x

ROI (TTM)40.02%

P/S Ratio (TTM)4.49x

Pretax Margin (5Y Avg)-44.86%

Revenue / Share (Annual)$6.49

Tangible BV / Share (Annual)$8.75

Forward P/E77.23x

Price vs S&P 500 (52W)17.25%

P/E Ratio (TTM)3.80x

Year-to-Date Return67.56%

5-Day Price Return-11.06%

EPS Normalized (Annual)$2.54

ROA (5Y Avg)-33.11%

Net Profit Margin (Annual)39.19%

Month-to-Date Return4.16%

Cash Flow / Share (TTM)$-5.39

EBITD / Share (Annual)$2.61

Operating Margin (Annual)37.75%

LT Debt / Equity (Annual)0.51x

ROI (5Y Avg)-37.60%

P/E Excl Extra (TTM)3.80x

LT Debt / Equity (Quarterly)4.53x

EPS Basic Excl Extra (TTM)$-1.54

P/TBV (Quarterly)92.41x

P/B Ratio (Annual)11.32x

Inventory Turnover (TTM)8.52x

Pretax Margin (TTM)-59.28%

Book Value / Share (Annual)$8.83

Price vs S&P 500 (13W)34.46%

Beta2.81x

P/FCF (Annual)7.00x

Revenue / Share (TTM)$2.51

ROE (TTM)283.08%

52-Week Low$6.20

vGradeC

gGradeD

mGradeB

vgmGradeC

NVAX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.38	-$0.32	+16.58%(+$0.06)
Q1 2026	May 6, 2026	-$0.24	-$0.06	+75.18%(+$0.18)
Q4 2025	Feb 26, 2026	-$0.49	$0.11	+122.48%(+$0.60)
Q3 2025	Nov 6, 2025	-$1.17	-$1.25	-7.01%(-$0.08)
Q2 2025	Aug 6, 2025	-$0.08	$0.62	+895.89%(+$0.70)

NVAX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

3.67

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	B	168.6x	-19.0%	—	—	$17.17

About Novavax Inc

Novavax Inc is a biotechnology company developing vaccines to prevent a broad range of human infectious diseases, with a focus on both established and emerging disease threats. The company conducts clinical-stage development of novel vaccine candidates, supported by its Swedish subsidiary's manufacturing operations. Its proprietary vaccine technology platform is designed for broad applicability across multiple infectious disease indications, with the majority of revenue generated from the United States.